AYTU
Aytu BioPharma, Inc.
Set alert
- YTD
- -25.77%
- 1 year
- -12.67%
- Open
- 1.99
- Prev close
- 1.99
- Mkt cap
- 20.97M
- Vol
- 97.26K
- Avg vol
- 34.39K
- EPS
- -1.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.90
- High
- 2.02
- Forward P/E
- 3.57
- Beta
- -1.40
- Short ratio
- 10.45
- Inst. own
- 34.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 1.76
- 200-d avg
- 2.53
- 1y target
- 8.00
Key statistics
- Market cap
- 9.22M
- Enterprise value
- 5.94M
- Trailing P/E
- 0.00
- Forward P/E
- 3.57
- PEG ratio
- 0.00
- Price / sales
- 0.11
- Price / book
- 0.32
- EPS (TTM)
- -1.70
- Beta
- -1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -19.56%
- Revenue (TTM)
- 81.00M
- Revenue growth
- -41.50%
- Free cash flow
- 4.81M
- Total cash
- 20.01M
- Total debt
- 16.42M
- Return on equity
- -47.24%
- Shares outstanding
- 6.15M
- Short % of float
- 3.92%
- 50-day average
- 1.76
- 200-day average
- 2.53
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.20 | — | — |
| Sep 26, 2024 | Jun 1, 2024 | 0.00 | -0.82 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.52 | — | — |
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | -0.04 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -1.48 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2023 | Maxim Group | init | — | Buy |
| May 31, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Aytu BioPharma, Inc.
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- aytubio.com
News
- Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
- Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
- Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15
- Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript
- Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
- Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call
- Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate
- Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
- Earnings Scheduled For September 22, 2026
- Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
Your note
Sign in to keep a note on AYTU — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DISBROW JOSHUA R. | Chief Executive Officer | Purchase | Jun 13, 2023 | 71,591 |
| DOCKERY CARL C | Director | Stock Award(Grant) | Nov 5, 2024 | 10,440 |
| JAIN ABHINAV | Director | Stock Award(Grant) | Nov 5, 2024 | 9,500 |
| LIU VIVIAN H | Director | Stock Award(Grant) | Nov 5, 2024 | 9,825 |
| NANTAHALA CAPITAL MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 13, 2024 | 0 |
| PYSZCZYMUKA GREG | Officer | Conversion of Exercise of derivative security | Sep 29, 2024 | 23,185 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 17.67% | 1,086,812 | 1.63M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 8.15% | 500,958 | 751.44K | Sep 29, 2024 |
| Armistice Capital, LLC | 3.84% | 236,000 | 354.00K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.22% | 74,723 | 112.08K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.73% | 45,102 | 67.65K | Sep 29, 2024 |
| Vanguard Group Inc | 0.45% | 27,888 | 41.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 33,273 | 49.91K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.45% | 27,888 | 41.83K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 8,054 | 12.08K | Oct 30, 2024 |
| DFA U.S. Targeted Value Portfolio | 0.10% | 6,160 | 9.24K | Jul 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.05% | 3,378 | 5.07K | Jul 30, 2024 |
| DFA U.S. Micro Cap Series | 0.05% | 3,228 | 4.84K | Jul 30, 2024 |